研究单位：[1]Cancer Foundation, China[2]Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021[3]Tongji Hospital, Tongji Medical College of Hust Wuhan, Hubei, China, 430030
This non-interventional study includes patients with advanced renal cell carcinoma who are treated with Sunitinib alone or combined with other systemic therapies. The aim of the trial is to increase knowledge about usage, dosage, efficacy and safety under conditions of routine use of Sunitinib.
